Potent pro-inflammatory cytokine (PubMed:10653850, PubMed:12794819, PubMed:28331908, PubMed:3920526). Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production (PubMed:3920526). Promotes Th17 differentiation of T-cells.
Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells (PubMed:10653850). Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6 (PubMed:12794819). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33377178, PubMed:33883744).
Acts as a sensor of S.pyogenes infection in skin: cleaved and activated by pyogenes SpeB protease, leading to an inflammatory response that prevents bacterial growth during invasive skin infection (PubMed:28331908)
Monomer. In its precursor form, weakly interacts with full-length MEFV; the mature cytokine does not interact at all (PubMed:17431422). Interacts with integrins ITGAV:ITGBV and ITGA5:ITGB1; integrin-binding is required for IL1B signaling (PubMed:29030430).
Interacts with cargo receptor TMED10; the interaction is direct and is required for the secretion of IL1B mature form (PubMed:32272059). Interacts with HSP90AB1; the interaction facilitates cargo translocation into the ERGIC (PubMed:32272059). Interacts with HSP90B1; the interaction facilitates cargo translocation into the ERGIC (PubMed:32272059)
Expressed in activated monocytes/macrophages (at protein level)
Click a pathway to open the interactive Reactome viewer.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to IL1B, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 173
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT02173548 | Heart Failure With Normal Ejection Fraction | Interleukin-1 Blockade in HF With Preserved EF | PHASE2 | COMPLETED |
| NCT01302795 | Pyoderma Gangrenosum | Canakinumab for Pyoderma Gangrenosum | PHASE2 | COMPLETED |
| NCT01302223 | Burns, Growth Factors, Combined Defect of, Inflammation, Cytokine Storm | Keratinocyte Growth Factor and Cytokines in Burns. | N/A | COMPLETED |
| NCT01213641 | Cryopyrin-associated Periodic Syndromes (CAPS), Familial Cold Autoinflam Syn (FCAS), Muckle-wells Syn (MWS), Neonatal Onset Multisystem Inflam Disease (NOMID) | Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients | N/A | COMPLETED |
| NCT00886769 | Systemic Juvenile Idiopathic Arthritis | Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) | PHASE3 | TERMINATED |
| NCT04025554 | Multiple Sclerosis | Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis | PHASE1, PHASE2 | COMPLETED |
| NCT00417417 | Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction | Rilonacept to Improve Artery Function in Patients With Atherosclerosis | PHASE2 | COMPLETED |
| NCT02082899 | Allergic Conjunctivitis | A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1) | PHASE2 | COMPLETED |
| NCT00420290 | End Stage Renal Disease | Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients | NA | COMPLETED |
| NCT04213274 | Schnitzler Syndrome, Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder) | Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome | PHASE2 | WITHDRAWN |